Portal de investigación
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carbone, David Paul
- Ciuleanu, Tudor-Eliade
- Schenker, Michael
- Cobo-Dols, Manuel
- Bordenave, Stephanie
- De Menezes, Juliana Janoski
- Reinmuth, Niels
- Richardet, Eduardo
- Cheng, Ying
- Mizutani, Hideaki
- Paz-Ares, Luis G.
- Lu, Shun
- John, Tom
- Zhang, Xiaoqing
- Hu, Nan
- Balli, David
- Baxi, Vipul
- Neely, Jaclyn
- Reck, Martin
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Carbone,DP,Ciuleanu,T,Schenker,M,Cobo,M,Bordenave,S,Juan,O,De Menezes,JJ et al. First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2023.